Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases

N/ACompletedNCT01248429

Centre Oscar Lambret154 enrolled

Overview

This study describes the elevation of CPK in patient treated for solid tumors by TKI

Study Type

OBSERVATIONAL

Enrollment

154

Conditions

Cancer Solid Tumor

Interventions

CPK dosageBIOLOGICAL

CPK dosage during a blood sample realized at least one week after the begining of the treatment

Clinical examOTHER

Examination of the patient for myalgia, cramps, medical history and concomitant medication

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week * Patient examined AND with a routine blood test planned * Patient informed of procedure for the study who was not opposed to it Exclusion Criteria: * Patient treated for malignant hemopathy * Patient no treated by inhibitor of thyrosine kinase or for less than 1 week * Patients with no routine blood laboratory tests planned

Locations (27)

Centre Paul Papin

Angers, France

Outcomes

Primary Outcomes

To evaluate the prevalence of the CPK increase

Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL

Time frame: Within 3 days after a clinical exam

Secondary Outcomes

Correlation myalgia/CPK increase

To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase

Time frame: During the clinical exam

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.